VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.
Canada will contribute around 75% of the U.S.-based company’s development costs and C$55.9 million ($42.2 million) for the project.
VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.
Get weekly health news
As per the agreement, signed last week, the company’s Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.
- Alleged defamation: Cape Breton fiddler Ashley MacIsaac files lawsuit against Google
- Flying or driving? Fuel shock means summer travel will happen ‘differently’
- Argyle Street businesses worried about construction 9 years after ‘disastrous’ project
- Alberta government prepares for 2026 wildfire season, introduces new support program
-
![]()
Exclusive: Chinese consulate allegedly tried to cancel Vancouver arts show -
![]()
‘Pearson is a disaster’: Poilievre backs Toronto island airport expansion -
![]()
Spirit Airlines goes out of business after 34 years, ending operations immediately -
![]()
Feds announce $250 million to expand training capacity for skilled trades within the CAF
There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.
Comments
Want to discuss? Please read our Commenting Policy first.